Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

Single-dose CAR-T therapy potentially curative in multiple myeloma by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

Arcellx, part of the U.S. Small & Mid Cap Biotechnology sector, has emerged as a key player in the development of CAR-T therapies for multiple myeloma, a type of blood cancer.

The multiple myeloma treatment market is expected to undergo significant changes, with CAR-T therapies projected to capture 30% of the market in the long term. Given Arcellx’s strong clinical data and ...

Patients received lymphodepleting chemotherapy with 300 mg/m 2 cyclophosphamide and 30 mg/m 2 fludarabine daily for 3 days, followed by an infusion of ide-cel at one of three dose levels: 150 × ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...